The diagnosis of human immunodeficiency virus type 1 (HIV-1) infection is currently based on antibody detection by immunoassays. During the first few weeks postinfection, the only evidence of HIV infection is the detection of the viral genome and, in approximately one third of patients, the occurrence of the acute retroviral syndrome. Serologic diagnosis can be made at 4 to 6 weeks by the detection of HIV antigen and days to weeks later by the sequential occurrence of antibodies to different HIV structural proteins.
HIV antigen determination may be useful in the diagnosis of HIV infection in neonates from seropositive women. Although p24 antigen detection in plasma is less sensitive for the detection of HIV in newborn, it performs with a sensitivity nearly comparable to those of PCR and virus isolation in children aged between 2 and 6 months (2) .
Biologic follow-up of HIV-1-infected individuals is based mainly on the surveillance of blood CD4 ϩ lymphocyte counts, p24 antigenemia, determination of viral load by quantitation of HIV-1 RNA copy number and virus isolation from peripheral blood monocytes and plasma, and biochemical parameters, such as the levels of ␤ 2 -microglobulin or neopterin in serum. In patients with CD4
ϩ counts of between 200 and 500/mm 3 , the percentage of patients positive for HIV-1 p24 antigen is approximately 20% (6) . Patients with CD4 ϩ counts of under 200/mm 3 and/or patients who have been diagnosed as having AIDS or AIDS-related complex show a higher p24 antigen prevalence rate (3, 12) . HIV antigen quantitation is useful as an easily measurable marker whose decline indicates the in vivo antiviral activities of anti-HIV agents and is helpful in the early evaluation of new agents (7) . A decline in p24 antigen levels under antiretroviral therapy is associated with a corresponding increase in CD4 ϩ cells. Increased detection of HIV antigenemia can be achieved after immune complex dissociation at a low pH by acid treatment of serum samples (10) . The percentage of p24 antigenpositive patients increases with every subsequent stage of HIV disease after immune complex dissociation. Furthermore, sera that contain detectable levels of p24 antigen in the standard assay frequently yield higher concentrations after acid treatment (7).
Actually, different assays for the quantitative detection of p24 antigen are available on the international market. Abbott, Coulter, and DuPont kits are used by the AIDS Clinical Trials Group Virology Committee for the monitoring of antiretroviral therapy in clinical studies (7) . In Germany, only two antigen assays (Abbott and Coulter) are licensed. In the present study, the kit performance of a new automated modular HIV antigen assay (Enzymun-Test HIV Ag) was compared with that of the Abbott HIV-1 antigen monoclonal antibody assay (Abbott HIV-1 Ag monoclonal assay) for a collective of 1,506 serum and plasma samples. For seroconversion panels, the Coulter p24 antigen assay served as a further reference method, and for serial serum samples obtained from the same individual under antiretroviral therapy, viral load was determined by nucleic acid sequence-based amplification (NASBA).
MATERIALS AND METHODS
Evaluation panel. A total of 1,506 serum samples originating from different patient collectives were comparatively investigated (see Table 1 ).
(i) In this study were included 63 sera regrouped in nine longitudinal HIV-1 seroconversion panels. These sequential sera were collected from individuals who had a primary symptomatic HIV-1 infection or a previous HIV-1-negative specimen and subsequent confirmed HIV-1-positive specimens and were purchased from commercial suppliers (Boston Biomedica Inc. (BBI) for panels E, I, J, L, P, Q, R, and S and New York Blood Center for panel A). The nine panels had been characterized by Western blot, antigen detection, virus isolation, and PCR.
(ii) The BBI PRA201 HIV antigen mixed titer panel includes a set of 20 samples with reactivities in currently available HIV antigen tests. The criterion for inclusion in this panel was reactivity in two or more antigen assays. Samples were chosen to provide a broad range of reactivity and to include samples from early seroconversion and samples from later infection.
(iii) Twofold dilution series of 11 HIV antigen-positive serum samples from HIV-infected individuals were included.
(iv) Follow-up serum samples (n ϭ 100) from 29 HIV-infected individuals in various stages of the disease (stages II to IV according to the Centers for Disease Control and Prevention [CDC] classification) were examined. From each patient, between three and six consecutive samples were available. All these patients were treated at the University Clinics (Frankfurt am Main, Germany) and were under antiretroviral therapy.
(v) Single serum specimens from HIV-infected individuals in CDC stage II (n ϭ 47), stage III (n ϭ 64), and stage IV (n ϭ 144) were investigated.
(vi) Potentially cross-reactive samples (n ϭ 563) obtained from patients with conditions unrelated to AIDS (organ transplant recipients, liver cirrhosis, renal failure, pregnancy, autoimmune diseases, rheumatoid factor positives, and acute illnesses attributable to infections caused by Toxoplasma gondii, cytomegalovirus, Epstein-Barr virus, herpes simplex virus, and hepatitis B and C viruses) were included.
(vii) Serum samples (n ϭ 494) from hospitalized patients were investigated. All these patients were hospitalized for various diseases and had tested anti-HIV and hepatitis B virus surface antigen negative.
Serum samples were stored at Ϫ20ЊC until tested. Enzymun-Test HIV-Ag. The Enzymun-Test HIV-Ag assay (Boehringer Mannheim, Mannheim, Germany) is a one-step sandwich assay for the detection of HIV-1 and HIV-2 antigens in human serum, plasma, and cell culture supernatants and is based on the biotin-streptavidin system. Biotinylated polyclonal anti-HIV antibodies and polyclonal 1,2-phenylenediamine-labeled anti-HIV antibodies react with the HIV antigen and bind to the streptavidin-coated solid polystyrene tube. The required minimal sample volume is 200 l. After a total incubation time of 5 h at 37ЊC, washing is performed and solid-phase-bound particles are visualized by di-ammonium 2,2Ј-azino-bis(3-ethylbenzothiazoline-6-sulfonate) substrate. The fully automated procedure is carried out on Boehringer Mannheim Enzymun-Test enzyme-linked immunosorbent assay (ELISA) processors ES 300 and ES 600/700. For quantitative HIV antigen detection, a quantitation panel consisting of two standards containing 6.8 and 310.3 pg of HIV antigen per ml is provided. The quantitation panel generates a standard curve from which the HIV antigen concentration of the specimen is determined by interpolation. HIV antigen levels are expressed in picograms per milliliter of plasma or serum. The limit of detection for this assay is 15 pg/ml of plasma or serum, as specified by the manufacturer. Repeatedly antigen-reactive samples are preincubated with a blocking antibody (human antibody to HIV) in order to confirm the presence of HIV antigen by specific antibody neutralization. If HIV antigen is present in the specimen, it forms an immune complex with the blocking antibody, thereby reducing the antigenic sites available for subsequent reaction. A specimen is considered positive if the reduction in absorbance of the neutralized specimen is 50% or greater compared with that of the nonneutralized control.
Abbott HIV-1 Ag monoclonal. The Abbott HIV-1 Ag monoclonal assay (Abbott, Delkenheim, Germany) is a three-step sandwich solid-phase enzyme immunoassay (EIA) used to detect HIV-1 p24 antigen. Polystyrene beads coated with monoclonal antibody to HIV-1 p24 antigen and polyclonal rabbit antibody to HIV-1 react with p24 antigen during the first and second incubations, respectively. During the third incubation step, goat antibody to rabbit immunoglobulin G conjugated with horseradish peroxidase binds to the rabbit antibody. Finally, o-phenylenediamine is added; after incubation, a yellow-orange color develops in proportion to the amount of HIV-1 antigen bound to the bead. Quantitative HIV-1 antigen detection is performed by using a quantitation panel consisting of five standards containing 0, 12.5, 25, 50, and 100 pg of HIV antigen per ml, and repeatedly reactive samples are retested after preincubation with a blocking antibody (human antibody to HIV) in order to confirm the presence of HIV-1 antigen by specific antibody neutralization. p24 antigen levels are expressed in picograms per milliliter; the limit of detection for this assay is 15 pg/ml, as specified by the manufacturer. Antigen-antibody complexes were dissociated by acid treatment according to the manufacturer's recommendations.
Coulter HIV-1 p24 antigen assay. The BBI PRA201 HIV antigen mixed titer panel was also investigated by the Coulter HIV antigen assay (Coulter, Hialeah, Fla.). The Coulter HIV-1 p24 antigen assay is a microtiter-based three-step EIA for the detection of HIV-1 antigen in serum, plasma, and cell culture supernatants. HIV-1 p24 antigen is bound to the microtiter plate by a murine monoclonal antibody. HIV antigen is detected by a biotinylated antibody which reacts with streptavidin coupled to horseradish peroxidase. After the addition of H 2 O 2 in the presence of tetramethylbenzidine substrate, a color reaction which is proportional to the antigen concentration develops.
Quantitative detection of HIV-1 RNA by NASBA. HIV-1 RNA was quantitated in 38 consecutive serum samples from nine patients under antiretroviral therapy by using NASBA technology (Organon Teknika, Turnhout, Belgium). NASBA is an isothermal HIV-1 RNA amplification which uses three enzymes, reverse transcriptase, RNase H, and T7 RNA polymerase. During the NASBA process, there is an accumulation of RNA complementary to the target sequence. The amplified fragments are detected by electrochemiluminescence in an automated instrument (NASBA QR System). Quantification is obtained by simultaneous competitive amplification of three different RNA constructs, internal RNA standards, that are spiked in scalar amounts into the plasma before extraction. The standards are specifically distinguished by hybridization with randomized 28-mer probes. Table 1 gives an overview of the comparative evaluation of the Enzymun-Test and Abbott HIV-1 Ag monoclonal assays. The Boehringer Mannheim and Abbott HIV antigen EIAs showed concordant results for the early detection of HIV antigen in all seroconversion panels. Although the same number of reactive samples were detected by both assays in the BBI antigen mixed titer panel, two samples gave discordant results. Sample PRA201-02, which is specified as borderline HIV antigen reactive and highly reactive for HIV antibody, tested low-level positive by the Enzymun-Test assay (sample/cutoff ratio, 1.0; 17.3 pg/ml) and negative by the Abbott HIV-1 Ag monoclonal assay. PRA201-04, which is supposed to be a borderline or nonreactive sample and highly HIV antibody reactive, tested negative by the Boehringer Mannheim assay and positive by the Abbott assay (sample/cutoff ratio, 2.1; 37.3 pg/ml). Both samples gave positive results by the Coulter assay. The 100 follow-up samples from 29 HIV-infected individuals under antiretroviral therapy gave divergent results. Six samples tested positive by the Enzymun-Test assay but were negative in the reference EIA. All these samples were confirmed to be positive by the Enzymun-Test HIV Ag assay since the optical density was reduced by more than 50% after incubation with blocking antibody. For the detection of HIV antigen in single serum samples from HIV-infected patients in different stages of HIV infection, a higher number of positive samples was detected by the Abbott HIV-1 Ag monoclonal assay in samples from patients in stages II and III of HIV infection. In contrast, the Enzymun-Test HIV Ag assay detected three more positive samples than did the Abbott assay from individuals in CDC stage IV of HIV infection. A higher sensitivity was achieved with the Boehringer Mannheim assay than with the alternative EIA in 11 dilution series of HIV antigen-positive serum samples. In eight samples, HIV antigen could be detected at higher dilutions by the Enzymun-Test assay (Table 2) .
RESULTS
To determine the specificity of the Enzymun-Test assay, a large number of potentially cross-reactive serum samples and specimens from hospitalized patients were investigated. Overall, the results for eight samples were repeatedly false positives. Four samples were obtained from patients with active cyto- The distribution of HIV antigen concentrations obtained by the Abbott and Boehringer Mannheim assays for serum samples from HIV-infected individuals and HIV-seronegative individuals is shown in Fig. 1 . In both tests, the great majority of serum samples showed index values (sample/cutoff ratios) of under 0.5 (Ͻ7 pg/ml). Overall, more samples gave borderline results in the Abbott HIV-1 Ag monoclonal assay than in the Enzymun-Test HIV Ag assay.
Standard curves for HIV antigen detection by the EnzymunTest HIV Ag and Abbott HIV-1 Ag monoclonal assays are shown in Fig. 2 . In the Abbott assay, lower index values were generated for the different standards than in the Boehringer Mannheim HIV antigen detection test.
Although the absolute values for the HIV antigen concentrations in serum samples were different in these two tests, good agreement was observed for the amplitude of HIV antigen concentration differences in the seroconversion panels and follow-up specimens from HIV-infected individuals under antiretroviral therapy. As shown in Fig. 3 , the coefficient of correlation was 0.91.
The results for HIV antigen detection in 38 consecutive samples from nine HIV-infected individuals were compared with those obtained by NASBA for viral RNA quantification. Viral RNA was detected by NASBA in all 38 samples, while the Enzymun-Test HIV Ag and Abbott HIV-1 Ag monoclonal assays yielded positive results for 35 (92.1%) and 34 (89.5%) samples, respectively. After dissociation of the antigen-antibody complexes, none of the four samples initially negative became positive in the Abbott p24 antigen assay. Figure 4 shows the concentration of HIV antigen and HIV-1 RNA copy number in 38 serial samples from nine HIV-infected patients. The correlation between quantitative antigen detection by both immunoassays and HIV-1 RNA quantitation by NASBA was relatively poor (r ϭ 0.089 for the Abbott HIV-1 Ag monoclonal assay versus NASBA and r ϭ Ϫ0.029 for the Enzymun-Test HIV Ag assay versus NASBA).
Overall, both tests showed relatively similar fluctuations in HIV antigen levels. In samples from patients 2, 4, 5, 6, and 8, changes in HIV antigen concentration were associated with corresponding changes in the HIV-1 RNA copy number per 100 l (data not shown). However, in samples from patients 1 and 7, the HIV antigen concentration and HIV-1 RNA copy number varied independently (data not shown).
In seroconversion panels BBI E, P, and Q, HIV-1 RNA could not be detected earlier by NASBA than by both HIV antigen ELISAs (Fig. 5) . For panels E and Q, both HIV antigen tests were positive at one blood sampling earlier than was NASBA.
DISCUSSION
In the present study, the Enzymun-Test assay was compared with the Abbott HIV-1 Ag monoclonal assay, which is a well established assay for quantitative detection of HIV-1 p24 antigen in serum and plasma samples. The performance characteristics of the Boehringer Mannheim antigen assay were com- 22021  80  40  36237  80  40  37848  80  40  19536  10  5  5100  10  5  23972  20  10  27048  5  5  26341  10  10  7024  10  5  18935  20  20  11750 on January 20, 2018 by guest http://jcm.asm.org/ parable to those of the reference assay. From a total of 1,506 serum and plasma samples, only 6 and 14 samples gave falsenegative and false-positive results, respectively, in comparison to the Abbott HIV-1 Ag monoclonal assay. One of these samples, however, was a true positive, since it also gave a positive result in the Coulter assay. As expected, some variability exists between HIV antigen kits, and this may reflect differences in the quality of the capture antibody, which is monoclonal in the Abbott assay and polyclonal in the Boehringer Mannheim assay, or differences in the matrix to which the capture antibody is bound. The monoclonal Abbott p24 EIA shows a higher sensitivity than does the polyclonal p24 assay (8) . Other researchers have reported the failure of monoclonal antibody to detect p24 antigen from certain strains of HIV (1, 13) . In this context, HIV-1 subtype O (5), which is highly divergent from other known HIV-1 subtypes, may not be detected by assays using monoclonal antibodies for the capture of p24 antigen. Although two HIV-1 strains with reduced homologies to HIV-1 reference strains were described in 1987 and 1991 (5, 14) , subtype O has become a major challenge for laboratory diagnosis of HIV infection, since it is endemic in Cameroon and screening antibody tests, especially those based on env peptides or the sandwich method, can lack sensitivity for this subtype (9) .
The capture antibody for the Enzymun-Test assay and the detector antibody for the Coulter kit are biotinylated; the Abbott capture and detector antibodies are not conjugated. While biotin is not a large molecule, its presence may be sufficient to reduce sensitivity by steric hindrance when patient antibody is complexed to antigen (11) . This negative effect may be counterbalanced by the high affinity of biotin for streptavidin. Overall, the Enzymun-Test assay showed a sensitivity equivalent to that of the reference assay. Theoretically, the Enzymun-Test assay may detect HIV-2 antigen. Because of the lack of a large panel of HIV-2 antigen-positive samples, the sensitivity of HIV-2 antigen detection could not be evaluated.
In monitoring antiretroviral therapy, it is important to employ the assay that is most sensitive to the presence of antigen and that reflects the viral activity most accurately. In this study, the Boehringer Mannheim assay provided the highest sensitivity in follow-up samples of patients under anti-HIV treatment. The changes in antigen concentration detected by the Boehringer Mannheim and Abbott assays showed good agreement with the dynamics of viral replication in five of eight patients, whereas both parameters, antigenemia and HIV RNA-emia, varied independently in the three remaining patients. No correlation was found between NASBA virus titers and HIV antigen levels in individual serum samples with the Abbott and Boehringer Mannheim kits. For example, in patient 7, high levels of HIV antigenemia were detected but the viral load was very low. These results are consistent with previous reports that some of the p24 antigen detected is not associated with intact virions (4). The detection of HIV antigen may some- times reflect a defective immune response which can no longer effectively complex or destroy viral proteins rather than increased viral replication (8) . The detection of HIV-1 RNA in serum or plasma could, therefore, more accurately reflect viral replication. According to Van Kerckhoven et al. (15) , no close correlation exists between the amount of HIV-1 RNA and the amount of p24 antigen or the titer of infectious virus in plasma or between this titer and the level of p24 antigen. Direct detection of cell-free HIV-1 RNA by PCR or NASBA is more sensitive than p24 antigen detection and quantitative virus culture. In our study, HIV-1 RNA was detected in 100% of the follow-up samples, while HIV antigen was present in 92.1% (EnzymunTest assay) and 89.5% (Abbott HIV-1 Ag monoclonal assay) of these samples.
HIV-1 infection could not be detected earlier by NASBA than by the Abbott and Boehringer Mannheim HIV antigen tests. Since the seroconversion samples from BBI were drawn in 1981 (panel E), 1989 (panel P), and 1990 (panel Q), the HIV-1 RNA concentration may have decreased under the detection limit of NASBA, especially in those specimens drawn in the very early phase of infection or directly after seroconversion.
The turnaround time, hands-on time, and costs have a significant impact on the usefulness of a test for routine diagnosis or monitoring of HIV infection. The total incubation times in the Abbott and Boehringer Mannheim assays are nearly equivalent. The hands-on time is shorter with the Enzymun-Test assay since the entire assay procedure is fully automated. In terms of the costs, both tests are relatively expensive if the list price is considered; one quantitative determination by either assay costs about 10 dollars.
In conclusion, the Enzymun-Test assay proved to be nearly equivalent to the Abbott HIV-1 Ag monoclonal assay in terms of sensitivity and specificity. The Boehringer Mannheim assay offers the advantage of fully automated detection of HIV antigen in a relatively rapid turnaround time.
